Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06145750 · ClinicalTrials.gov registry record · NA
Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer
A NA study, sponsored by Delfi Diagnostics.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT06145750: Completed NA study, sponsored by Delfi Diagnostics.
NCT06145750 is a NA study that has completed, run by Delfi Diagnostics. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06145750, a NA study, has completed, sponsored by Delfi Diagnostics.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether availability of DNA Evaluation of Fragments for Early Interception (DELFI) Lung Cancer Screening Test, FirstLook™ to practicing physicians affects overall lung cancer screening rates among their patients who are recommended and eligible for screening based on 2021 United States Preventive Services Task Force (USPSTF) but are not up to date with it. DELFI hypothesized that patients in the care of physicians or practice groups who have FirstLook™ will have increased lung screening rates compared to patients in the care of physicians or practice groups who do not have access to FirstLook™.
Interventions
- DIAGNOSTIC_TEST Ability to order FirstLook™
- OTHER Continuing Medical Education for Lung Cancer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-10-31 |
| Est. Completion | 2025-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06145750
The ClinicalTrials.gov registry entry for NCT06145750 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Delfi Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ability to order FirstLook™ is the first listed.
NCT06145750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06145750 about?
NCT06145750 is a clinical study titled "Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer". The purpose of this study is to determine whether availability of DNA Evaluation of Fragments for Early Interception (DELFI) Lung Cancer Screening Test, FirstLook™ to practicing physicians affects overall lung cancer screening rates among their patients who are recommended and eligible for screening...
What is the current status of trial NCT06145750?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2023-10-31. Estimated completion is 2025-08-31.
What interventions are being tested in trial NCT06145750?
The interventions under investigation include: Ability to order FirstLook™ (DIAGNOSTIC_TEST), Continuing Medical Education for Lung Cancer (OTHER).
Who is sponsoring clinical trial NCT06145750?
This trial is sponsored by Delfi Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.